Ovid Therapeutics (OVID) Operating Income Growth (3y) (2019 - 2026)

Ovid Therapeutics (OVID) Operating Income Growth (3y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Oculis Holding AG 67,042.03 Bn 67,041.74 Bn - 16.96%
2 Nanobiotix 1,908.00 Bn 1,907.94 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 471.84 Bn 467.05 Bn 1.35 Bn 38.78%
5 Vertex Pharmaceuticals 122.13 Bn 114.88 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 70.01 Bn 61.26 Bn 3.31 Bn -12.10%
7 Belite Bio 62.34 Bn 62.34 Bn - -
8 Argenx Se 55.93 Bn 50.74 Bn 1.41 Bn 69.02%
9 Alnylam Pharmaceuticals 37.49 Bn 34.48 Bn 959.66 Mn 55.96%
10 Ovid Therapeutics 120.41 Mn -35.11 Mn - -6.22%

Historic Data

Download Data
DateValue
Mar 31, 2026 -6.22%
Dec 31, 2025 -0.33%
Sep 30, 2025 0.74%
Jun 30, 2025 29.22%
Mar 31, 2025 8.28%
Dec 31, 2024 25.90%
Sep 30, 2024 -4.23%
Jun 30, 2024 -12.75%
Mar 31, 2024 -28.03%
Dec 31, 2023 5.56%
Sep 30, 2023 9.82%
Jun 30, 2023 15.08%
Mar 31, 2023 9.80%
Dec 31, 2022 11.00%
Sep 30, 2022 8.59%
Jun 30, 2022 -2.40%
Mar 31, 2022 -5.00%
Dec 31, 2021 -26.15%
Sep 30, 2021 3.93%
Jun 30, 2021 -2.71%